Jade Biosciences, Inc. (JBIO) SEC Filings & Earnings Calls

Preclinical data may not translate to clinical efficacy; Phase 1 trial not yet initiated; regulatory and competitive risks.

“Forward-looking statements highlight risks including clinical delays, adverse events, and unanticipated costs.”

Clinical-stage company with no approved products; net loss; reliance on pipeline success.

“Net loss of $55.8M; no revenue; cash runway into Q4 2028.”

Clinical development risk

“We have not completed any clinical trials, and we have no products approved for commercial sale.” · word for word

Capital requirement risk

“We will require substantial additional capital to finance our operations in the future.” · word for word

Competition risk

“We face competition from entities that have developed or may develop products for the diseases addressed by our product candidates.” · word for word

Reliance on third parties

“We rely on collaborations and licensing arrangements with third parties, including Paragon.” · word for word

Single product dependency

“We are substantially dependent on the success of JADE101.” · word for word

Clinical Development Risk

“Our programs are in the clinical and preclinical stages of development and may fail in development or suffer delays that materially and adversely affect our viability.” · word for word

No Approved Products / Revenue

“We have no products approved for commercial sale, have not generated any revenue from product sales to date, and continue to incur significant research and development and other expenses related to our ongoing operations.” · word for word

Dependence on JADE101

“We are substantially dependent on the success of JADE101, and our current and anticipated future clinical trials of such product candidate may not be successful.” · word for word

Reliance on Paragon / Related Party

“We rely on collaborations and licensing arrangements with third parties, including Paragon. If we are unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, our business could be negatively impacted.” · word for word

Tariff / BIOSECURE Act Risk

“The U.S. BIOSECURE Act, which was enacted in December 2025, prohibits federal agencies from procuring or using any biotechnology equipment or services from biotechnology companies of concern.” · word for word

Pre-revenue stage with increasing net losses; dependent on pipeline success

“Net loss $40.4M; no revenue; R&D and G&A expenses rising as company advances clinical programs.”

Clinical trial execution risk

“Phase 1 data for JADE101 and JADE201 expected in 2027; Phase 2 start Q2 2026; delays or negative data could impact valuation.”

Potential dilution from inducement stock awards

“1,750,000 shares reserved for inducement plan”

Pre-revenue biotech with increasing net loss and R&D spend; no approved products or revenue stream.

“Net loss increased to $127.4M in FY2025 from $47.0M in prior period; R&D expenses rose to $93.1M.”

Dependence on clinical trial success for pipeline candidates JADE101, JADE201, JADE301.

“Pipeline candidates are in early clinical stages; Phase 1 data for JADE101 expected Q2 2026.”

Pre-revenue biotech; clinical and regulatory risk for pipeline candidates.

“Clinical-stage biotechnology company; no approved products.”

Dilution risk from equity issuance

“3,214,286 shares issued at $14.00 per share”

Going concern risk

“Substantial doubt about the Company's ability to continue as a going concern due to significant operating losses and negative cash flows from operations since inception.” · word for word

Pre-revenue clinical-stage company with no approved products

“We have no products approved for sale and have not generated any revenue from product sales.” · word for word

Dependence on Paragon for discovery and licensing

“We rely on our collaboration with a third party, Paragon, for a substantial portion of our discovery capabilities and for the rights necessary to develop and commercialize our product candidates.” · word for word

Single-source manufacturing reliance on WuXi Biologics

“We currently have a single source for our supply of our product candidates and recently entered into an agreement with a second supplier.” · word for word

Geopolitical risk from Chinese CMO exposure

“WuXi Biologics (Hong Kong) is a subsidiary or affiliate of WuXi Biologics, which was previously identified in the U.S. legislation proposed in 2024 known as the BIOSECURE Act as a biotechnology 'company of concern.'” · word for word